Research by Dr Adrienn Petreczky

All of our attendees carry out a piece of research in an area of MS clinical practice or treatment that interests them.

If you would like to contact Dr Petreczky, drop us a line and we’ll put you in touch where possible.

 

Aim

To review the disease-modifying treatments (DMTs) prescribing practices of the neurology department at the James Cook University Hospital, specifically:

  • the number of patients receiving DMTs
  • the types of DMTs used and how often they are administered
  • what the trends in prescribing have been over the past four years
  • how this compares with other local hospital Trusts.

Headlines

  • Disease modifying treatments (DMTs) are one of the most effective methods of management relapsing-remitting MS.
  • Information was gathered via a retrospective audit through:
    • NHS Bluteq data
    • the local DMT database
    • a review of the Trust audit database

Key findings

  • There are 443 patients on a DMT in Middlesborough, which is comparable to York and Leeds
  • There are currently 11 DMTs available and under prescription, with Ocrelizumab expected additionally soon.
  • 78% of patients are prescribed first line DMTs, comparable to York and Leeds; and Cladribine has low numbers of users in line with the other local Trusts as it only recently became accessible to the region.
  • 22% on patients are on second line DMTs (Gilenya and Tysabri); a growing trend.
  • There is a gradual increase in those being prescribed first line oral DMTs.
  • Interferon remains the most frequently prescribed first line DMT.
  • South Tees is comparable to Leeds in terms of costs per capita spent on DMTs.
    • York is spending the least due to high numbers of patients using first line DMT Tecfidera
    • Sunderland is spending the most due to high numbers of patients on second line treatment Lemtrada.

Core recommendations

  • Audit the prescribing trend for Lemtrada (second line DMT) and injectable DMTs.
  • Ensure that hospital management and local commissioners are aware of the gradual increase in numbers of patients receiving DMTs because of the impact on the service, from bed availability to staff and monitoring requirements.

 

Take action